Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Expands By 392.0%

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totaling 36,900 shares, agrowthof392.0% from the June 30th total of 7,500 shares. Based on an average trading volume of 19,400 shares, the short-interest ratio is presently 1.9 days. Based on an average trading volume of 19,400 shares, the short-interest ratio is presently 1.9 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 10,715 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $3.24 on Tuesday. Inventiva has a 52-week low of $1.53 and a 52-week high of $4.05. The stock has a 50 day moving average price of $3.28 and a 200-day moving average price of $3.10.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.